Chemours Analyst Price Targets - Benzinga

SPY766.40+0.13%QQQ714.44+0.31%BTC/USD79,786.20−0.44%DIA523.01+0.01%GLD367.05−0.21%TLT81.680.00%

Premium Services

Premium Services

The Chemours Co

CCNYSE

Trade with Public

Trade with Public

$12.87

0.060.47%

Last update: Oct 26, 5:40 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Chemours Analyst Price Targets - Benzinga

Chemours Analyst Price Targets

Wall Street analyst price targets and consensus rating for Chemours (CC).

Price Target Range — 13 Quarters

Analyst Consensus — 7 Analysts

3Buy

4Hold

Consensus RatingNeutral# Analysts7Avg. Consensus PT$17Upside to Avg. PT+35.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 20, 2026	Truist Securities	Peter Osterland	PT Cut	Buy	$24→$20
Oct 14, 2026	Mizuho	John Roberts	Downgrade	Outperform→Neutral	$18→$15
Oct 13, 2026	Barclays	Aleksey Yefremov	Initiate	Equal-Weight	$16
Oct 5, 2026	UBS	Joshua Spector	PT Cut	Neutral	$18→$16
Sep 30, 2026	Mizuho	John Roberts	PT Cut	Outperform	$20→$18
Aug 13, 2026	JP Morgan	Jeffrey Zekauskas	PT Cut	Neutral	$22→$15
Aug 13, 2026	BMO Capital	John McNulty	PT Cut	Outperform	$26→$18
Aug 10, 2026	UBS	Joshua Spector	Downgrade	Buy→Neutral	$29→$18
Aug 6, 2026	RBC Capital	Arun Viswanathan	PT Cut	Outperform	$26→$22
Aug 6, 2026	Truist Securities	Peter Osterland	PT Cut	Buy	$30→$24
Jul 1, 2026	Mizuho	John Roberts	PT Cut	Outperform	$30→$25
May 21, 2026	JP Morgan	Jeffrey Zekauskas	PT Raise	Neutral	$17→$22
May 11, 2026	Morgan Stanley	Vincent Andrews	PT Raise	Equal-Weight	$17→$21
May 11, 2026	RBC Capital	Arun Viswanathan	PT Raise	Outperform	$26→$29
May 8, 2026	UBS	Joshua Spector	PT Raise	Buy	$29→$30
Apr 28, 2026	Truist Securities	Peter Osterland	PT Raise	Buy	$27→$30
Apr 9, 2026	UBS	Joshua Spector	PT Raise	Buy	$23→$29
Apr 9, 2026	Truist Securities	Peter Osterland	PT Raise	Buy	$21→$27
Mar 5, 2026	Mizuho	John Roberts	PT Raise	Outperform	$17→$21
Feb 25, 2026	Goldman Sachs	Duffy Fischer	PT Raise	Neutral	$14→$18

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Chemours, Lowers Price Target to $20

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $24 to $20.

Benzinga Newsdesk

This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR received a new $60 target.

Avi Kapoor

PRO
Mizuho Downgrades Chemours to Neutral, Lowers Price Target to $15

Mizuho analyst John Roberts downgrades Chemours (NYSE:CC) from Outperform to Neutral and lowers the price target from $18 to $15.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Chemours with Equal-Weight Rating, Announces Price Target of $16

Barclays analyst Aleksey Yefremov initiates coverage on Chemours (NYSE:CC) with a Equal-Weight rating and announces Price Target of $16.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on Chemours, Lowers Price Target to $16

UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $18 to $16.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Chemours, Lowers Price Target to $18

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $20 to $18.

Benzinga Newsdesk